Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen

Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

RPRX has been the topic of several other research reports. Morgan Stanley initiated coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They issued an "overweight" rating and a $51.00 price objective on the stock. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $47.33.

Royalty Pharma Stock Down 0.1%

Shares of NASDAQ RPRX traded down $0.05 during midday trading on Friday, hitting $34.86. 5,346,891 shares of the stock traded hands, compared to its average volume of 3,646,705. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.56 and a current ratio of 1.56. Royalty Pharma has a one year low of $24.05 and a one year high of $35.38. The business has a 50 day moving average price of $33.14 and a two-hundred day moving average price of $31.21. The company has a market cap of $19.60 billion, a PE ratio of 18.84, a P/E/G ratio of 1.79 and a beta of 0.48.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. On average, equities analysts predict that Royalty Pharma will post 4.49 EPS for the current year.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds have recently made changes to their positions in the stock. Applied Finance Capital Management LLC grew its holdings in Royalty Pharma by 3.0% during the 1st quarter. Applied Finance Capital Management LLC now owns 11,265 shares of the biopharmaceutical company's stock valued at $351,000 after buying an additional 329 shares in the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in Royalty Pharma by 0.7% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares in the last quarter. National Bank of Canada FI increased its holdings in Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 371 shares during the period. Sherbrooke Park Advisers LLC lifted its stake in Royalty Pharma by 1.1% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock worth $890,000 after purchasing an additional 380 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after purchasing an additional 388 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.